Aveanna Reports Q3 2026 Revenue Growth of 11.8% and Adjusted EBITDA Growth of 25%

Aveanna reported Q3 2026 revenue of $695.5M, up 11.8%, and Adjusted EBITDA of $100.1M, up 25% YoY. Gross margin increased 11.8% to $226.8M. Revenue grew across all segments. YTD free cash flow improved by $55M. Liquidity was $492.1M as of October 3, 2026, including $197.8M in cash.

Original reporting
Published Nov 13, 2026, 1:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 1:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aveanna Reports Q3 2026 Revenue Growth of 11.8% and Adjusted EBITDA Growth of 25% — source image
Decision brief

The 30-second read

$AVAHBullishMed
01

Why it matters

The earnings beat signals operational strength and may prompt analysts to raise forecasts, supporting a short‑term rally.

02

Market read

First‑time earnings disclosure with solid growth; relevant for healthcare‑sector traders.

03

What to watch

Potential headwinds from reimbursement policy changes or staffing shortages in home‑health services.

Relevance 7/10Novelty 7/10Timing: after‑hours release

Background

Aveanna Healthcare Holdings Inc (AVAH) is a provider of home health, hospice, private duty, and medical solutions services.

Company-level read

Ticker impact

$AVAHBullishHigh confidence
Context

Aveanna Healthcare reported Q3 2026 revenue of $695.5M (+11.8%) and adjusted EBITDA of $100.1M (+25%) – first public disclosure of these earnings figures.

Expected impact

likely upward pressure as the market prices in better‑than‑expected growth

Evidence & confidence

Revenue and EBITDA both rose double‑digit year‑over‑year, exceeding typical expectations for a mid‑cap healthcare services firm.

Market effects

May boost sentiment for the home‑health and hospice sector as a peer shows strong growth.

Limited to U.S. healthcare services investors.

Low; impact confined to sector‑specific investors.

Counterpoint

If guidance falls short of market expectations despite growth, the stock could face disappointment.

Key entities

  • Aveanna Healthcare Holdings Inc

    U.S. listed provider of home‑health and related services.

Related articles

$AVAHHighAI 8/10

Aveanna Healthcare Earnings Call Signals Broader Growth, Higher Guidance

Aveanna Healthcare (AVAH) reported Q3 revenue of $695.5M, up 11.8%, and adjusted EBITDA of $100.1M, up 25%. All segments grew, with Home Health and Hospice up 15.6%, Private Duty Services up 11.6%, and Medical Solutions up 9.1%. The company raised 2026 guidance to revenue above $2.695B and adjusted EBITDA above $374M, citing growth in preferred payers and state rate enhancements. Management highlighted caregiver shortages and California rate uncertainty as risks.

$AVAHMedAI 8/10

What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call

Aveanna Healthcare (AVAH) reported Q3 revenue growth of 15.6% to $72.1M in Home Health and Hospice, and 9.1% to $49.2M in Medical Solutions. CEO Shaner cautioned that 20-25% growth is unsustainable. The company secured $30M in California funding for rate increases, aiming for permanency. Aveanna reconfirmed long-term growth targets and plans to focus acquisitions on Home Health and Hospice. It reported $492M in liquidity and $1.52B in variable-rate debt, all hedged through 2029.

$AVAHHigh

Raymond James reiterates Strong Buy on Aveanna stock after beat

Raymond James reiterated a Strong Buy rating and $15.00 price target for Aveanna Healthcare (AVAH) after its Q3 2026 results beat estimates. AVAH reported adjusted EBITDA of $100.1M, 7.5% above consensus, and raised its 2026 EBITDA guidance to at least $374M. The stock trades at $13.09, with 13% upside to the target. RBC Capital increased its price target to $16.00, citing positive market positioning.

$AVAHHighAI 8/10

Aveanna Healthcare shares fall 6% despite third quarter beat

Aveanna Healthcare (AVAH) reported Q3 earnings of $0.23 per share, beating estimates by $0.02, with revenue of $695.5M, up 11.8% YoY. Despite this, shares fell 6.04% pre-market due to fiscal 2026 guidance that aligned with analyst expectations. The company raised its full-year revenue guidance to over $2.695B and EBITDA guidance to over $374M. All three business segments contributed to revenue growth, and net income rose to $45.5M from $14.1M YoY.